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immune deficiencies and inherited metabolic disorders. UCB has been shown to have a number of attractive advantages compared with BM and PBSCs including (i) rapid availability, 2 (ii) lack of donor attrition, (iii) absent risk to donor, (iv) lower rate and severity of acute and chronic GVHD than would be expected using a volunteer unrelated donor (VUD) with a similar degree of HLA disparity 3,4 and, therefore, (v) an expansion of the donor pool for patients in whom it is currently difficult to find VUD, that is those with rare HLA phenotypes or from ethnic minorities.
Most importantly, OS or EFS and relapse incidence following UCBT in children has been shown to be at least equivalent compared with BMT, despite inferior engraftment, in both the related and unrelated donor settings. [4] [5] [6] 
UCBT in adult recipients
The application of UCBT in adult recipients has been more cautious because of the reported slower and inferior engraftment incidences, 7 reflecting the lower cell dose infused, a key determinant of both engraftment and survival. 8 More encouraging results were published by the International Bone Marrow Transplant Registry and the European Blood and Marrow Transplant Group in 2004. 9, 10 Both studies included large numbers of patients (600 and 682 patients, respectively) with primary acute leukaemia who had received a single-unit UCBT or BMT following myeloablative conditioning. The International Bone Marrow Transplant Registry study also included patients with secondary acute leukaemia, myelodysplasia and CML. In the European Blood and Marrow Transplant Group comparison of predominantly mismatched UCBT (94% mismatched) with HLA-matched BMT, UCBT was associated with delayed neutrophil engraftment and a lower incidence of acute GVHD compared with BMT. However, the incidences of chronic GVHD, TRM, relapse incidence and leukaemia-free survival were equivalent. 10 The International Bone Marrow Transplant Registry compares the outcome of UCBT with matched and mismatched BMT. Engraftment was slower following UCBT and mismatched BMT compared with matched BMT, and acute GVHD was most likely to occur after mismatched BMT. TRM, treatment failure and overall mortality were lower in those receiving a matched BMT, but there was no difference between those receiving a UCBT compared with mismatched BMT. 9 The demonstration that UCBT is at least equivalent to mismatched BMT in adults has led to increasing international interest in the role of UCBT among physicians caring for adult patients. Much research interest is currently focused on abrogating the duration of neutropenia using approaches that include (i) augmenting the infused cell dose by ex vivo expansion 11 or addition of 'carrier' haploidentical CD34 þ selected PBSCs 12 and (ii) improved homing by direct intraosseous injection of UCB (ongoing studies in the United States and Europe). Perhaps the most successful to date has been the coinfusion of two unrelated units, an approach pioneered at the University of Minnesota. 13 
Conditioning regimens
Much of the published outcome data for UCBT have come from international registries, which have included heterogeneous patient groups, conditioning regimens and GVHD prophylaxis. 4, 9, 10 However, the most commonly used myeloablative regimens have incorporated the use of CY, TBI and fludarabine with CsA and either prednisolone or mycophenolate mofetil GVHD prophylaxis. The Minneapolis group has used fludarabine 75 mg/m 2 , CY 120 mg/kg and 1320 cGy TBI with CsA and mycophenolate mofetil GVHD prophylaxis before double-unit UCBT. 13 All evaluable patients achieved neutrophil engraftment at a median of 23 days with a cumulative plt engraftment of 71% at day 180. All patients achieved complete donor chimerism. The probability of leukaemia-free survival was 57% at 1 year and 72% at 1 year in those with acute leukaemia in remission at the time of transplant or with CML. Another interesting regimen has been reported recently by Sanz et al. 14 Using thiotepa 150 mg/m 2 , BU 9.6 mg/m 2 , fludarabine 150 mg/m 2 and ATG 8 mg/kg with CsA and prednisolone GVHD prophylaxis before single-unit UCBT, they reported a cumulative incidence of neutrophil engraftment of 89% at a median of 22 days and a TRM of only 14% at day 100 and 20% at day 180.
A number of investigators have also explored the use of reduced-intensity conditioning regimens to extend access to UCBT in older patients, those with comorbidities and those who have been extensively pre-treated (summarized in Table 1 ). The most promising to date appears to be the University of Minnesota approach incorporating fludarabine 200 mg/m 2 , CY 50 mg/kg and 200 cGy TBI with CsA and mycophenolate mofetil GVHD prophylaxis. A recent Eurocord/SFGM-TC survey has shown that patients undergoing UCBT using this approach had a significantly superior neutrophil recovery (87 vs 65%, Po0.01), TRM at 1 year (24 vs 60%) and disease-free survival (43 vs 16%) compared with all other protocols. 20 
Current status of UCBT in the United Kingdom
The inclusion of UCB into routine practice within the UK transplant community has been slow for a number of reasons.
These include the lack of a national strategy and available clinical trials; caution about the utility of UCB in adults before 2004; and successful outcomes using alternate strategies where a fully matched VUD or sibling was not available, (i) the inclusion of T-cell depletion into the conditioning protocols (allowing selection of mismatched donors) and (ii) expertise in paediatric centres in performing haploidentical haematopoietic cell transplantation. The number of UCB transplants performed in the United Kingdom (until the end of 2006) is 183 (British Society of Blood and Marrow Transplantation, BSBMT; http://www.bsbmt.org/cms_pages/ 48-2006-Activity-by-Indication), mostly paediatric patients. Over the last 4 years, the number of cord blood procedures has increased rapidly, with a marked increase in the number of adult recipients (approximately 25 in 2006/7, o5 in the preceding years). In 2007, the Anthony Nolan Trust, as the UK registry hub, imported 70 UCB units for clinical transplantation, representing an increase of over 214% of the cord blood activity in the United Kingdom. Although UCB transplantation still comprises a small proportion of national haematopoietic cell transplantation practice, it is recognized that a significant number of patients would benefit if UCB were used. Data from the Anthony Nolan Trust and retrospective analyses from a number of transplant centres within the United Kingdom show that, in up to 30% of Caucasian patients, a 9-10/ 10-matched VUD cannot be found, and that in some cases the search and/or procurement of stem cells may take up to 3-6 months, with the potential to adversely affect transplant outcome. In patients from ethnic minorities, this figure is up to 70% because of an underrepresentation of equivalent donors on the international registries. Recent patterns of immigration to the United Kingdom have further diversified the ethnic mix in our patients (http://www.migrationinformation.org/datahub/ countrydata/data.cfm).
Establishment of a UK UCB working group
To address these issues, a meeting was held at the Royal Society of Medicine, arranged by Dr Rachael Hough and Dr Paul Veys, and supported by the UK Cord Blood Charity and the Royal Society of Medicine. This was well attended by senior transplant physicians, research scientists and cord blood bankers from all over the United Kingdom (Appendix 1). An international keynote speaker, Dr Juliet Barker, gave a state of the science lecture and provided much input into the discussion that occurred thereafter. The primary aim of this meeting was to propose a national strategy for the inclusion of UCB into our current clinical transplantation practice. The two areas of critical importance for agreement were the use of standard conditioning protocols and donor selection strategies in all centres.
Clinical protocols
Two myeloablative regimens were discussed. The Valencia BU-based regimen 14 ( (Table 2) . This protocol will be developed through the BSBMT Clinical Trials Committee. Two protocols using the Minneapolis non-ablative regimen 15 have been developed. A BSBMT Clinical Trials Committee/CCLG-approved national clinical research protocol was discussed (Table 2 ). UCLH will be the sponsor and their CTU will run the study with a full-time study coordinator. Funding has been secured from the Sue Harris Trust and Chugai Pharma. The aim is to enter a total of 60 patients over a 3-year period, and the study will begin imminently, pending approval from the Human Tissue Authority and the National Research Ethics Service. A KCH-sponsored protocol is also being used and has been approved by the IRB, Ethical Committee and MHRA. A small number of patients have thus far been transplanted on this protocol. The chief differences between the two studies mentioned are the number of cord units used (double cord unit in all patients in the KCH study; single or double based on cell dose and HLA disparity in the BSBMT study) and the use of ATG (all patients in the KCH study; not included in the BSBMT study).
The inclusion of ATG in the conditioning protocol was a topic for further discussion.
A major concern has been the incidence and aggressiveness of EBV reactivation and post transplant lymphoproliferative disease (PTLD) seen in patients transplanted using ATG-containing reduced-intensity conditioning regimens. 21 This does not appear to be a problem when using MA protocols. The response to treatment (with rituximab), in patients who develop PTLD, appears to be unpredictable. The early experience at KCH is in line with these reports. Although EBV reactivation is reported on frequently, it was noted that other pathogens (for example, adenovirus) were also increased compared with VUD. When omitting ATG, the incidence of GVHD may be increased, but this has been relatively easy to treat in some centres. In addition, graft failure is not increased in patients who have been previously/recently treated with intensive chemotherapy. The inclusion of fludarabine and an increase in the dose of TBI in some conditioning protocols have compensated for the exclusion of ATG. The opinion of the meeting was that the use of ATG should be carefully considered and should be restricted to certain clinical situations (for example, previously untreated patients). It was felt that protocols should contain recommendations about the type and frequency of microbial monitoring, as well as general guidelines for thresholds for treatment intervention. It was recognized that this was a key area for future research and is currently the subject of a BSBMT Clinical Trials Committee study.
Donor selection algorithms
A number of donor selection algorithms were discussed and accepted by the members of the meeting (Table 3a-d) . The 'scoring system' is based on HLA matching and total nucleated cell numbers (in the case of UCB), and it was recognized that such a system would help to produce a hierarchy for decision making. HLA matching is based on matching for 10 alleles at five loci (HLA-A, -B, -C, -DRB1 and -DQB1) to reflect our current UK practice. However, it is recognized that mismatching for HLA-DQB1 may have less significance than mismatching for other loci, suggesting that a DQB1 mismatch should be selected above any other mismatch. An 8/10 matched transplant (where one of the mismatches is at DQB1) may have a similar outcome to a 9/10 matched transplant. Other factors that influence this hierarchy would include where speed is essential and therefore a cord may be selected over a VUD, if there is likely to be a delay; and if immunotherapy is very likely to be required (for example, donor lymphocyte infusion), a less well-matched VUD may be selected over UCB. It was also recognized that, in some circumstances, a haploidentical family donor may also provide an equivalent or superior alternative stem cell source for transplantation as outlined in Table 3a -d. It is unclear at this stage how the use of double UCB units may affect selection criteria. It was noted that data in cord blood transplantation were becoming available on outcomes when selection was based on other parameters (for example, CD34 counts) and that, therefore, these selection algorithms will need regular review and updating. Cord blood unit selection is recognized to differ in many ways from unrelated donor selection. Thus, it will be necessary for centres using cord blood as a stem cell source to collaborate closely with experts in UCB unit selection to gain experience in this area.
Recommendations
1. We consider that UCB should be considered as an alternative source of haematopoietic stem cells to unrelated donor transplants for those lacking a suitably matched unrelated donor, and that, within the European Blood and Marrow Transplant Group guidelines, such transplants come under the definition of a 'clinical option' rather than a 'developmental' intervention. 22 2. We recommend that UCB transplants should currently be performed using the nationally agreed and approved conditioning protocols. 3. We recommend that the nationally agreed donor selection algorithms should be used. 4. We recommend that transplant centres actively collaborate with individuals who have expertise in cord blood unit selection (for example, registry-based or trial coordinators). 5. We recommend that nationally agreed protocols for the monitoring and intervention in viral (and other pathogen) reactivation should be developed as a matter of urgency. 6. Given the complex nature of these procedures, UCB transplantation should be performed only in centres with extensive and appropriate expertise in VUD transplantation (assuming compliance with the points above). We suggest that centres wishing to perform UCB transplantation should identify a clinician with a specific interest in this field, who will contribute to ongoing national discussions and act as a contact person for dissemination of new data as they become available. Abbreviation: TNC ¼ total nucleated cell count. These algorithms consider only HLA matching and cell dose and may be modified by other important factors (for example, availability of donor, need for further cell infusions from same donor). HLA matching in VUD refers to matching at high/intermediate resolution for HLA-A, -B, -C, -DRB1 and -DQB1 (that is, 10 alleles). HLA matching in UCB refers to matching at low resolution for HLA-A, and -B and intermediate/high resolution for HLA-DRB1 (that is, 6 alleles).
7. We recommend a regular review of the UCB transplant outcomes in the United Kingdom, under the auspices of the BSBMT, CCLG and any other relevant bodies. To ensure this, we have set up a UCB working group within the BSBMT. 8. Other topics should be addressed in an ongoing fashion including determination of the optimal size of the cord blood inventory; funding sources; quality issues and coherent (science) research strategies, for example, stem cell expansion. 9. The need to design novel and innovative clinical trials was recognized; however, this should be delayed until UCB transplantation has been successfully established using the existing agreed protocols.
